Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PGK1 | P00558 | 6/20 | 0.42 |
| ▸ | GSK3B | P49841 | 1/20 | 0.37 |
| ▸ | MAP4K2 | Q12851 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.36 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.36 |
| ▸ | HMGCR | P04035 | 1/20 | 0.35 |
| ▸ | BCL6 | P41182 | 1/20 | 0.35 |
| ▸ | TUBB1 | Q9H4B7 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12473140 | 0.79 | CYP3A4 (0.38) | L3MBTL1 | |
| SCHEMBL2937347 | 0.76 | LMNA (0.46) | TUBB1 | |
| SCHEMBL20620238 | 0.73 | TUBB1 (0.34) | TUBB1 | |
| SCHEMBL3319344 | 0.72 | GAA (0.47) | L3MBTL1 | |
| SCHEMBL3717227 | 0.72 | PDE4B (0.41) | PGK1L3MBTL1PDE4BPDE4D | |
| SCHEMBL1239663 | 0.72 | BCL6 (0.45) | BCL6TUBB1 | |
| SCHEMBL2823284 | 0.72 | GAA (0.47) | — | |
| SCHEMBL1239107 | 0.72 | MAPT (0.44) | PGK1BCL6 | |
| SCHEMBL16173475 | 0.71 | CYP3A4 (0.43) | HMGCRTUBB1 | |
| SCHEMBL2001415 | 0.71 | LMNA (0.43) | TUBB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3483149-B1 | BENZO[D]THIAZOLE DERIVATIVE OR SALT THEREOF, AND PHARMACEUTICAL COMPOSITION INCLUDING SAME | YUHAN CORP (KR) | 2021-01-13 | — | — | EP | disclosed |
| US-10689331-B2 | IDO inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2020-06-23 | — | — | US | disclosed |
| US-10383859-B2 | Benzo[d]thiazole derivative or salt thereof, and pharmaceutical composition including same | YUHAN CORPORATION (KR) | 2019-08-20 | — | — | US | disclosed |
| US-20190142809-A1 | Benzo[D]Thiazole Derivative Or Salt Thereof, And Pharmaceutical Composition Including Same | YUHAN CORPORATION (KR) | 2019-05-16 | — | — | US | disclosed |
| EP-3483149-A1 | BENZO[D]THIAZOLE DERIVATIVE OR SALT THEREOF, AND PHARMACEUTICAL COMPOSITION INCLUDING SAME | Yuhan Corporation (KR) | 2019-05-15 | — | — | EP | disclosed |
| US-20190002402-A1 | IDO INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2019-01-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190142809-A1 | Benzo[D]Thiazole Derivative Or Salt Thereof, And Pharmaceutical Composition Including Same | ILK, SBDS, BDKRB1 | PGK1 3363/4885GSK3B 2505/4885MAP4K2 499/4885 |
| US-10383859-B2 | Benzo[d]thiazole derivative or salt thereof, and pharmaceutical composition including same | ILK, SBDS, BDKRB1 | PGK1 3363/4885GSK3B 2505/4885MAP4K2 499/4885 |
| US-20190002402-A1 | IDO INHIBITORS | IDO1, IDO2, INMT | PGK1 280/4885GSK3B 42/4885MAP4K2 1778/4885 |
| US-10689331-B2 | IDO inhibitors | IDO1, IDO2, INMT | PGK1 280/4885GSK3B 42/4885MAP4K2 1778/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.